Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose: preliminary study.

Falconi M, Contro C, Ballabio M, Bassi C, Salvia R, Pederzoli P

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver1 Feb 2002Cited by 8 (Europe PMC)

PMID11926556DOI10.1016/s1590-8658(02)80242-0PepBankPUB-11926556

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
After pancreaticoduodenectomy, 24-hour output was 208.6+/-41.3 ml after lanreotide versus 253.9+/-72.4 ml after placebo, without a significant reduction.
In plain wordsAfter pancreatic surgery, 24-hour pancreatic output did not decrease significantly with lanreotide compared with placebo.
Peptide
Lanreotide
Outcome
No significant change24-hour pancreatic output
Study
n = 7
Comparator
placebo
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
0.5 mg single dose · subcutaneousAs given in this study (human).
Measurements
24-h pancreatic output volume (mean)
208.6 ml
after lanreotide
24-h pancreatic output volume (+/- value)
41.3 ml
after lanreotide
24-h pancreatic output volume (mean)
253.9 ml
after placebo
24-h pancreatic output volume (+/- value)
72.4 ml
after placebo
Source sentences
Summary
In the seven patients completing the study, the 24-h output volume was 208.6+/-41.3 and 253.9+/-72.4 ml after lanreotide and placebo, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Lanreotide induced a statistically significant reduction in the output volume with respect to placebo in the first 6 hours after administration, but not thereafter.
Summary · context
The volume and composition of pancreatic secretion were evaluated after one single subcutaneous injection of lanreotide 0.5 mg or placebo in a randomised, double-blind cross-over trial.
Report a problemFND-1192655601
02HumanRandomized controlled trialEfficacy outcome
After pancreaticoduodenectomy, pancreatic output during the first 6 hours was 48.1+/-14.7 ml after lanreotide versus 77.6+/-21.4 ml after placebo.
In plain wordsAfter pancreatic surgery, pancreatic output during the first six hours was lower after lanreotide than placebo.
Peptide
Lanreotide
Outcome
DecreaseFirst 6-hour pancreatic output
Study
n = 7
Comparator
placebo
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
0.5 mg single dose · subcutaneousAs given in this study (human).
Measurements
First 6-h pancreatic output volume (mean)
48.1 ml
after lanreotide
First 6-h pancreatic output volume (+/- value)
14.7 ml
after lanreotide
First 6-h pancreatic output volume (mean)
77.6 ml
after placebo
First 6-h pancreatic output volume (+/- value)
21.4 ml
after placebo
Source sentences
Summary
During the first 6 hours values were 48.1+/-14.7 and 77.6+/-21.4 ml (p=0. 02).
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients, undergoing pancreaticoduodenectomy for malignancy, were enrolled in the trial.
Summary · context
The volume and composition of pancreatic secretion were evaluated after one single subcutaneous injection of lanreotide 0.5 mg or placebo in a randomised, double-blind cross-over trial.
Report a problemFND-1192655602
03HumanRandomized controlled trialEfficacy outcome
After pancreaticoduodenectomy, lanreotide and placebo did not differ significantly in qualitative composition of 24-hour pancreatic secretion.
In plain wordsAfter pancreatic surgery, lanreotide and placebo did not differ significantly in pancreatic fluid composition.
Peptide
Lanreotide
Outcome
No significant changePancreatic secretion composition
Study
n = 7
Comparator
placebo
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
0.5 mg single dose · subcutaneousAs given in this study (human).
Source sentences
Summary
No significant difference between treatments was detected in the qualitative composition of 24-h pancreatic secretion, although bicarbonate secretion remained lower after the active drug at all the observation intervals.
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients, undergoing pancreaticoduodenectomy for malignancy, were enrolled in the trial.
Summary · context
The volume and composition of pancreatic secretion were evaluated after one single subcutaneous injection of lanreotide 0.5 mg or placebo in a randomised, double-blind cross-over trial.
Report a problemFND-1192655603
04HumanRandomized controlled trialEfficacy outcome
After pancreaticoduodenectomy, bicarbonate secretion remained lower after lanreotide than placebo at all observation intervals, although no significant difference was detected in the qualitative composition of 24-hour pancreatic secretion.
In plain wordsAfter pancreatic surgery, bicarbonate was lower after lanreotide than placebo at all measured times, although overall fluid composition did not differ significantly.
Peptide
Lanreotide
Outcome
DecreaseBicarbonate secretion
Study
n = 7
Comparator
placebo
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
0.5 mg single dose · subcutaneousAs given in this study (human).
Source sentences
Summary
No significant difference between treatments was detected in the qualitative composition of 24-h pancreatic secretion, although bicarbonate secretion remained lower after the active drug at all the observation intervals.
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients, undergoing pancreaticoduodenectomy for malignancy, were enrolled in the trial.
Summary · context
The volume and composition of pancreatic secretion were evaluated after one single subcutaneous injection of lanreotide 0.5 mg or placebo in a randomised, double-blind cross-over trial.
Report a problemFND-1192655604
05HumanNon-randomized trialPharmacokinetics
After pancreaticoduodenectomy, peak lanreotide levels occurred 15-30 min after injection.
In plain wordsAfter pancreatic surgery, lanreotide levels peaked 15-30 minutes after injection.
Peptide
Lanreotide
Outcome
Not applicableTime to peak levels
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.5 mg single dose · subcutaneousAs given in this study (human).
Measurements
Time to peak lanreotide level
15 to 30 min
after single subcutaneous injection
Source sentences
Summary
Peak lanreotide levels were detected 15-30 min after drug injection.
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients, undergoing pancreaticoduodenectomy for malignancy, were enrolled in the trial.
Summary · context
The volume and composition of pancreatic secretion were evaluated after one single subcutaneous injection of lanreotide 0.5 mg or placebo in a randomised, double-blind cross-over trial.
Report a problemFND-1192655605
06HumanNon-randomized trialSafety outcome
After pancreaticoduodenectomy, clinical and laboratory tolerability of lanreotide was good.
In plain wordsAfter pancreatic surgery, clinical and laboratory checks indicated good lanreotide tolerability.
Peptide
Lanreotide
Outcome
Not applicableClinical and laboratory tolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0.5 mg single dose · subcutaneousAs given in this study (human).
Source sentences
Summary
Clinical and laboratory tolerability was good.
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients, undergoing pancreaticoduodenectomy for malignancy, were enrolled in the trial.
Summary · context
The volume and composition of pancreatic secretion were evaluated after one single subcutaneous injection of lanreotide 0.5 mg or placebo in a randomised, double-blind cross-over trial.
Report a problemFND-1192655606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.